Leiv Lea is the Chief Financial Officer at Corvus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancers and other diseases. With more than 25 years of experience in finance within the biotechnology and pharmaceutical sectors, Lea brings deep expertise in strategic financial planning, capital markets, and operational leadership to guide Corvus through its growth phases. Prior to joining Corvus in September 2021, Lea served as CFO at Aduro Biotech, Inc., where he led financial operations during a period of transformative partnerships, equity financings, and the company's eventual acquisition by Chinook Therapeutics in 2020. His earlier roles include Vice President of Finance at Opexa Therapeutics, Director of Finance at Genentech (a member of the Roche Group), and various senior finance positions at biotech firms such as Somaxon Pharmaceuticals and PDL BioPharma. Throughout his career, Lea has orchestrated multiple successful IPOs, follow-on offerings, and mergers, raising hundreds of millions in capital to fuel clinical development and commercialization initiatives. At Corvus, Lea oversees all financial aspects, including investor relations, budgeting, treasury management, and SEC compliance, playing a key role in securing funding to advance the company's lead programs like soquelitinib and ciforadenant. His strategic acumen has been instrumental in positioning Corvus for long-term success in the competitive biotech landscape, ensuring robust financial health amid evolving market dynamics.